Impact of risankizumab on disease symptoms in patients with non-pustular palmoplantar psoriasis: Post hoc analysis of the phase IIIb IMMprint study
Recommended Citation
Lebwohl M, Bukhalo M, Stein Gold LF, Glick B, Llamas-Velasco M, Sanchez-Rivera S, Cotter D, Pan A, Yue C, Patel M, Espaillat R, Kaplan B, Spelman L, Bissonnette R. Impact of risankizumab on disease symptoms in patients with non-pustular palmoplantar psoriasis: Post hoc analysis of the phase IIIb IMMprint study. Australas J Dermatol 2025; 66:22-23.
Document Type
Conference Proceeding
Publication Date
5-29-2025
Publication Title
Australas J Dermatol
Abstract
Aims: Non-pustular palmoplantar psoriasis (PPPsO) is a chronic disease causing painful plaques on the palms and soles, impacting quality of life. The phase IIIb IMMprint trial showed higher efficacy of Risankizumab (RZB) over placebo (PBO) in achieving “clear” or “almost clear” skin (ppIGA 0/1) (33.3% vs. 16.1%, p = 0.006). This analysis investigates RZB's impact on PPPsOsymptoms. Methods: IMMprint was a phase IIIb multicenter, randomised, double-blind, PBO-controlled study evaluating RZB in PPPsO patients. The analysis focused on the Patient Global Assessment of Skin Pain (PGA-SP) and Psoriasis Symptom Scale (PSS) at 16 and 52 weeks. Outcomes included changes from baseline and achievement of Minimum Clinically Important Difference (MCID) in skin pain, redness, itch, and burning. Missing data were addressed using Non-Responder Imputation incorporating multiple imputation for categorical endpoints and Mixed-Effect Model Repeat Measurement for continuous ones. Results: Among 174 patients, 87 were randomised to RZB and 87 to PBO, with 46.0% and 51.7% females, respectively. The mean age was 56.9y (RZB) and 53.9y (PBO). Mean baseline PSS scores were 10.5 (RZB) and 8.9 (PBO), and PGA-SP scores were 6.8 (RZB) and 5.3 (PBO). In patients with baseline PGA-SP ≥ 4, mean PGA-SP changes at 16wks were - 3.3 (RZB) and - 0.9 (PBO), improving to -4.9 (RZB/RZB) and - 4.8 (PBO/RZB) by 52wks. MCID for pain improvement was achieved by 67.2% (RZB) vs. 45.1% (PBO) at 16wks and 70.3% (RZB/RZB) vs. 88.9% (PBO/RZB) at 52wks (Table). PSS 0/1 achievement at wk16 (RZB vs. PBO) was 52.1% vs. 40.5% for pain, 49.3% vs. 25.7% for redness, 42.5% vs. 25.7% for itching, and 56.2% vs. 44.6% for burning. By wk52, these increased to 64.4%/75.4% for pain, 61.6%/ 69.6% for redness, 56.2%/68.1% for itching, and 65.8%/71.0% for burning. Conclusions: RZB provides significant relief from PPPsO symptoms by 16wks, with continued improvement up to 52wks in this difficult-to-treat population.
Volume
66
First Page
22
Last Page
23
